- Home
- PRLD vs CIGL Comparison
PRLD vs CIGL Comparison
Compare PRLD & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- CIGL
- Stock Information
- Founded
- PRLD 2016
- CIGL 1997
- Country
- PRLD United States
- CIGL Singapore
- Employees
- PRLD N/A
- CIGL N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- CIGL Diversified Commercial Services
- Sector
- PRLD Health Care
- CIGL Consumer Discretionary
- Exchange
- PRLD Nasdaq
- CIGL Nasdaq
- Market Cap
- PRLD 44.0M
- CIGL 46.7M
- IPO Year
- PRLD 2020
- CIGL 2025
- Fundamental
- Price
- PRLD $1.01
- CIGL $3.00
- Analyst Decision
- PRLD Strong Buy
- CIGL
- Analyst Count
- PRLD 3
- CIGL 0
- Target Price
- PRLD $4.00
- CIGL N/A
- AVG Volume (30 Days)
- PRLD 219.4K
- CIGL 7.9M
- Earning Date
- PRLD 11-05-2025
- CIGL 01-01-0001
- Dividend Yield
- PRLD N/A
- CIGL N/A
- EPS Growth
- PRLD N/A
- CIGL N/A
- EPS
- PRLD N/A
- CIGL N/A
- Revenue
- PRLD $7,000,000.00
- CIGL $10,490,668.00
- Revenue This Year
- PRLD N/A
- CIGL N/A
- Revenue Next Year
- PRLD N/A
- CIGL N/A
- P/E Ratio
- PRLD N/A
- CIGL N/A
- Revenue Growth
- PRLD N/A
- CIGL N/A
- 52 Week Low
- PRLD $0.61
- CIGL $1.40
- 52 Week High
- PRLD $2.72
- CIGL $31.06
- Technical
- Relative Strength Index (RSI)
- PRLD 43.80
- CIGL N/A
- Support Level
- PRLD $1.03
- CIGL N/A
- Resistance Level
- PRLD $1.26
- CIGL N/A
- Average True Range (ATR)
- PRLD 0.11
- CIGL 0.00
- MACD
- PRLD -0.03
- CIGL 0.00
- Stochastic Oscillator
- PRLD 0.00
- CIGL 0.00
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.